

\*\* TX STATUS REPORT \*\*

AS OF MAR 26 2002 11:59 PAGE.01

32 DATE TIME  
03/26 11:58TO/FROM  
917030729306MODE  
EC--SMIN/SEC  
00'30"PGS  
002JOB#  
096STATUS  
OK#10/a  
10-31-02  
RP

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Roth et al.

) Art Unit: 1625

Serial No. : 09/678,682

) Examiner: Morris, P.

Filed : October 3, 2000

For : SUBSTITUTED INDOLINES WHICH INHIBIT RECEPTOR TYROSINE  
KINASES

Docket No. : 5/1275

Confirmation No.: 6798

## Certificate of Transmission under 37 CFR 1.8

I hereby certify that this correspondence is being facsimile transmitted to the United States Patent and Trademark Office (attn: TC 1600 at 703-872-9306) on March 26, 2002.

By: Alan Stempel  
Reg. No. 28,991Assistant Commissioner for Patents  
Washington, D.C. 20231RESPONSE TO OFFICE ACTION


Sir:

In response to the Office action mailed on February 27, 2002, please enter the following elections.

### ELECTIONS

Applicants hereby elect to prosecute claims directed to the invention of Group I, that is, the invention of claims 1-7, drawn to compounds and compositions, classified in classes 540, 544, 546 and 548, various subclasses.

Applicants further elect the following single disclosed species: 3-Z-[1-(4-(N-((4-methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone. The elected species is disclosed on page 226 as compound No. (473) and has the following structure:



The elections are made without traverse.

Respectfully submitted,

Alan Stempel  
Attorney for Applicant(s)  
Reg. No. 28,991

Patent Department  
Boehringer Ingelheim Corp.  
900 Ridgebury Road  
P.O. Box 368  
Ridgefield, CT. 06877  
Tel.: (203) 798-4868